普来乐联合顺铂治疗恶性胸膜间皮瘤的疗效观察  

Clinical observation on the efficacy and safety of pemetrexed plus cisplatin for patients with malignant pleural mesothelioma

作　　者：郝长城 

机构地区：[1]山东省潍坊市第二人民医院胸外科,山东潍坊261041

出　　处：《现代肿瘤医学》2011年第5期911-912,共2页Journal of Modern Oncology

摘　　要：目的:观察普来乐联合顺铂治疗恶性胸膜间皮瘤的疗效。方法:选择36例恶性胸膜间皮瘤患者,男24例,女12例,年龄35-67岁,平均年龄46.3±2.6岁。给予普来乐联合顺铂进行治疗。结果:胸痛、呼吸困难等症状基本消失,胸水体征消失或明显减轻,全身状况好转;5例症状有所减轻,但仍有原不适主诉存在,全身状况所有不明显改善。36例病人完全缓解0例,部分缓解20例,无效16例,有效率为55.6%。结论:普来乐联合顺铂治疗恶性胸膜间皮瘤疗效显著。Objective： To investigate the efficacy of pemetrexed plus cisplatin for patients with malignant pleural mesothelioma.Methods： All 36 patients with malignant pleural mesothelioma were treated by 4 cycles of pemetrexed plus cisplatin.Of the 36 patients there were 24 males and 12 females,the average age was 46.3±2.6 years.Results： Of all 36 patients,the overall response rate was 55.6%,20 cases received partial remission,no case received complete remission.The major toxicity was nausea and vomit.Only one patient had myelosuppression.Conclusion： Pemetrexed plus cisplatin is a safe and effective regimen in malignant pleural mesothelioma.

关 键 词：普来乐 顺铂 恶性胸膜间皮瘤 

分 类 号：R734.3[医药卫生—肿瘤]